This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
medical-devices: Archive
Integer Holdings (ITGR) Q2 Earnings Top Estimates, Margins Up
by Zacks Equity Research
Integer Holdings' (ITGR) second-quarter results reflect robust Medical Sales, along with strength in all the product lines.
ABTNegative Net Change BSXPositive Net Change DGXPositive Net Change ITGRPositive Net Change
earnings medical medical-devices
3 Reasons Why You Should Hold HealthEquity (HQY) Stock Now
by Zacks Equity Research
HealthEquity's (HQY) sustained strength in HSAs raises optimism about the stock.
BSXPositive Net Change ISRGPositive Net Change GMEDPositive Net Change HQYPositive Net Change
medical medical-devices
Revvity (RVTY) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Revvity's (RVTY) second-quarter results are likely to reflect strong performance in the Diagnostics segment.
MCKPositive Net Change AXGNNegative Net Change NARINegative Net Change RVTYPositive Net Change
medical medical-devices
Three Reasons to Retain Avanos (AVNS) Stock in Your Portfolio
by Zacks Equity Research
Avanos' (AVNS) strong product line and focus on R&D raise optimism about the stock.
BSXPositive Net Change UHSPositive Net Change HOLXPositive Net Change AVNSPositive Net Change
medical medical-devices
DexCom's (DXCM) Q2 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
DexCom's (DXCM) second-quarter 2024 earnings surpass expectations while revenues fall short. The Sensor segment and CGM system expansion drive growth. Shares fall.
DGXPositive Net Change UHSPositive Net Change DXCMNegative Net Change ABMPositive Net Change
medical medical-devices
Hologic (HOLX) Buys Endomag to Boost Breast Cancer Solutions
by Zacks Equity Research
Hologic (HOLX) acquires Endomag for $310M, enhancing its breast cancer surgery portfolio with innovative technologies like Magseed and Magtrace, aiming to improve patient care and outcomes globally.
DGXPositive Net Change UHSPositive Net Change HOLXPositive Net Change HAEPositive Net Change
medical medical-devices
Implied Volatility Surging for United Therapeutics (UTHR) Stock Options
by Zacks Equity Research
Investors need to pay close attention to United Therapeutics (UTHR) stock based on the movements in the options market lately.
UTHRPositive Net Change
medical medical-devices
Amedisys (AMED) Q2 Earnings Top Estimates, Gross Margin Down
by Zacks Equity Research
Amedisys (AMED) delivers year-over-year growth in all three of its segmental revenues in the second quarter of 2024.
ABTNegative Net Change AMEDPositive Net Change DGXPositive Net Change ISRGPositive Net Change
earnings medical medical-devices
Lower Volume Likely to Hurt GE HealthCare's (GEHC) Q2 Earnings
by Zacks Equity Research
GE HealthCare's (GEHC) second-quarter results are likely to witness declining segmental revenues in imaging, ultrasound and patient care. The bottom-line results may reflect better pricing.
MCKPositive Net Change AXGNNegative Net Change NARINegative Net Change GEHCPositive Net Change
medical medical-devices
Terumo (TRUMY) Unit Reveals WEB 17 Device Effective in Aneurysms
by Zacks Equity Research
Terumo's (TRUMY) subsidiary MicroVention's WEB 17 device, used in treating intracranial aneurysms, demonstrates high safety and effectiveness in the CLEVER study.
DGXPositive Net Change UHSPositive Net Change HAEPositive Net Change TRUMYPositive Net Change
medical medical-devices
Alphatec's (ATEC) New EOS Insight System to Boost Spine Care
by Zacks Equity Research
Alphatec (ATEC) announces the commercial launch of its EOS Insight, an end-to-end spine surgery platform powered by standardized EOSedge scans and artificial intelligence.
BSXPositive Net Change UHSPositive Net Change HOLXPositive Net Change ATECPositive Net Change
medical medical-devices
Factors Setting the Tone for Ecolab's (ECL) Q2 Earnings
by Zacks Equity Research
Ecolab's (ECL) second-quarter results are likely to reflect continued segmental strength.
ECLPositive Net Change MCKPositive Net Change AXGNNegative Net Change NARINegative Net Change
medical medical-devices
Zacks Initiates Coverage of Vaso With Neutral Recommendation
by Debanjana Dey
Discover why Zacks rates Vaso as "Neutral", being the first on Wall Street to initiate coverage on the stock. Explore VASO's strategic market presence and financial health amid market challenges.
VASOPositive Net Change
medical medical-devices
Should You Buy BancFirst (BANF) After Golden Cross?
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
BANFPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Redwood Trust (RWT)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
RWTPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Reasons to Retain DENTSPLY SIRONA (XRAY) in Your Portfolio Now
by Zacks Equity Research
DENTSPLY SIRONA (XRAY) continues to gain traction from a robust product portfolio. However, macroeconomic factors like weakened global demand, rising costs and forex woes persist.
BSXPositive Net Change BDXPositive Net Change XRAYNegative Net Change HOLXPositive Net Change
medical medical-devices
The Zacks Analyst Blog Highlights SAP, Abbott Laboratories, Citigroup, Team and Vaso
by Zacks Equity Research
SAP, Abbott Laboratories, Citigroup, Team and Vaso are part of the Zacks top Analyst Blog.
CPositive Net Change ABTNegative Net Change SAPPositive Net Change TISINegative Net Change VASOPositive Net Change
business-services computers finance medical medical-devices
West Pharmaceutical (WST) Misses on Q2 Earnings, Lowers '24 View
by Zacks Equity Research
West Pharmaceutical's (WST) second-quarter results reflect a declining demand for products across its segments amid elevated customer destocking.
HOLXPositive Net Change MASINegative Net Change WSTPositive Net Change GMEDPositive Net Change
earnings medical medical-devices
Edwards Lifesciences (EW) Q2 Earnings Meet Mark, Margins Crash
by Zacks Equity Research
Edwards Lifesciences (EW) reports strong contributions from the TMTT product group in the second quarter of 2024.
ABTNegative Net Change DGXPositive Net Change ISRGPositive Net Change EWPositive Net Change
earnings medical medical-devices
Intuitive Surgical and Hooker Furnishings have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Intuitive Surgical and Hooker Furnishings are part of the Zacks Bull and Bear of the Day article.
MSFTPositive Net Change ISRGPositive Net Change PANWPositive Net Change HOFTPositive Net Change CRWDPositive Net Change
computers consumer-discretionary medical-devices
Chemed (CHE) Q2 Earnings Miss Estimates, Margins Expand
by Zacks Equity Research
Chemed's (CHE) VITAS segment delivers impressive revenue growth and margin expansion in the second quarter of 2024.
ABTNegative Net Change DGXPositive Net Change ISRGPositive Net Change CHEPositive Net Change
earnings medical medical-devices
Do Options Traders Know Something About Cencora (COR) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Cencora (COR) stock based on the movements in the options market lately.
CORPositive Net Change
medical medical-devices
New Strong Buy Stocks for July 25th
by Zacks Equity Research
BSVN, OKTA, SVM, SFIX and XAIR have been added to the Zacks Rank #1 (Strong Buy) List on July 25, 2024.
SVMPositive Net Change OKTAPositive Net Change SFIXPositive Net Change BSVNPositive Net Change XAIRPositive Net Change
consumer-discretionary medical-devices
Top Analyst Reports for SAP, Abbott Laboratories & Citigroup
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including SAP SE (SAP), Abbott Laboratories (ABT) and Citigroup Inc. (C), as well as two micro-cap stocks Team, Inc. (TISI) and Vaso Corporation (VASO).
CPositive Net Change ABTNegative Net Change OKEPositive Net Change SAPPositive Net Change SNPSPositive Net Change TISINegative Net Change IQVPositive Net Change VASOPositive Net Change
business-services computers finance medical medical-devices
Veeva Systems' (VEEV) Vault EDC to Boost Vita Global's Workflow
by Zacks Equity Research
Veeva Systems' (VEEV) Vault EDC is likely to aid the CRO in delivering a better experience to patients, research sites and sponsors.
BSXPositive Net Change BDXPositive Net Change GMEDPositive Net Change VEEVPositive Net Change
medical medical-devices